

Injectable Medication HCPCS/DOFR Crosswalk Reference Table Updated— 1st Quarter 2019

Approved updates are effective April 24, 2019

On January 15, 2019, the Health Net* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The approved updates are effective April 24, 2019, and are listed on pages 2 through 4. The DOFR categories into which injectable medications are placed mirror the DOFR matrix categories located in the Health Net *Provider Participation Agreement (PPA)*. The update includes:

- The addition of 14 new medications and their DOFR categories.
- Updates and changes to 34 injectable medication procedure codes.

ADDITIONAL INFORMATION

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library, located on Health Net's provider website at provider.healthnet.com.

Providers are encouraged to access Health Net's provider portal online at provider.healthnet.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at provider_services@healthnet.com within 60 days, by telephone or through the Health Net provider website as listed in the right-hand column.

THIS UPDATE APPLIES TO
CAL MEDICONECT
PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

PROVIDER SERVICES

provider_services@healthnet.com
 Los Angeles County – 1-855-464-3571
 San Diego County – 1-855-464-3572
www.healthnet.com

PROVIDER COMMUNICATIONS

provider_communications@healthnet.com

ADDITIONS TO INJECTABLE MEDICATION HCPCS/DOFR CROSSWALK

The following medications have been approved by the Health Net P&T Committee as additions to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table. P&T Committee members include physicians and representatives from Health Net participating physician groups (PPGs).

HCPCS* Codes	Brand Name	Generic Name	Primary Category	Secondary Category
J0841	Anavip®	Injection, crotalidae immune f(ab') ₂ (equine), 120 mg	Therapeutic injection	
C9399, J9999	Belrapzo™	Bendamustine hydrochloride injection, for intravenous use	Therapeutic injection	Chemotherapy*
J0185	Cinvanti®	Aprepitant, injection, 1 mg	Therapeutic injection	Chemo adjunct*
J3590	Emgality™	Galcanezumab-gnlm	Self-injectable	
J3590	Gamifant®	Emapalumab-lzsg injection, for intravenous use	Therapeutic injection	
Q5109	Ixifi™	Infliximab-qbtx, biosimilar, 10 mg	Therapeutic injection	
C9399, J7199	Jivi®	Antihemophilic factor (recombinant), PEGylated-auclyophilized powder for solution, for intravenous use	Therapeutic injection	Blood/blood products for hemophilia
J9999	Khapzory™	Levoleucovorin for IV soln	Therapeutic injection	Chemo adjunct*
J9999	Libtayo®	Cemiplimab-Rwlc IV Soln	Therapeutic injection	Chemotherapy*
J9999	Lumoxiti™	Moxetumomab pasudotox-tdfk for injection, for intravenous use	Therapeutic injection	Chemotherapy*
J3490	Tegsedi™	Inotersen injection, for subcutaneous use	Self-injectable	
C9399, J3490	Trivisc™	Sodium hyaluronate for intra-articular injection	Therapeutic injection	
J9999	Truxima™	Rituximab-abbs	Therapeutic injection	Chemotherapy*
Q5111	Udenyca™	Pegfilgrastim-CBQV	Self-injectable	Chemo adjunct*

UPDATES/CHANGES TO INJECTABLE MEDICATION PROCEDURE CODES OR MEDICATIONS

Updates to the Injectable Medication HCPCS/DOFR Crosswalk Reference Table are based on changes or updates to HCPCS codes or changes in medication descriptions or availability. The following are changes to injectable medications currently listed in the crosswalk.

HCPCS* Codes	Brand Name	Generic Name	Comment
J1454	Akynzeo®	Fosnetupitant and palonsetron for injection, for intravenous use	Changed from C9033
J9057	Aliqopa™	Copanlisib for injection, for intravenous use	Changed from C9030
C9035	Aristada Initio™	Aripiprazole lauroxil extended-release injectable suspension	Changed from C9399, J3490
J9229	Besponsa®	Inotuzumab ozogamicin for IV soln	Changed from J9028
J0567	Brineura®	Cerliponase alfa for intraventricular use	Changed from C9014
J0185	Cinvanti®	Aprepitant injectable emulsion, for intravenous use	Changed from C9463
J0834	Cosyntropin 0.25 mg	Cosyntropin, 0.25 mg	Changed from J0833
J0584	Crysvita®	Burosumab-twza injection, for subcutaneous use	Changed from J3590
J7318	Durolane®	Sodium hyaluronic, for single intra-articular injection 60mg/3ml	Changed from C9465
J0517	Fasenra™	Benralizumab, for subcutaneous use	Changed from C9466
J7177	Fibryga®	Fibrinogen concentrate (human) lyophilized powder for reconstitution	Changed from C9399, J3590
J0599	Haegarda®	C1 esterase inhibitor (human) for subcutaneous inj	Changed from C9015
J7170	Hemlibra®	Emicizumab-kxwh injection, for subcutaneous use	Changed from Q9995
J3245	Ilumya™	Tildrakizumab-asmn 100 mg/ml injection, for subcutaneous use	Changed from J3590
J9173	Imfinzi®	Durvalumab soln for IV infusion	Changed from C9492
Q2042	Kymriah®	Tisagenlecleucel, up to 250 million car-positive viable T cells, including leukapheresis and dose preparation procedures, per infusion	Changed from Q2040
J3398	Luxturna™	Voretigene neparvovec-rzyl	Changed from C9032
J3397	Mepsevii™	Vestronidase alpha-vjbk	Changed from C9399, J3590

HCPCS* Codes	Brand Name	Generic Name	Comment
Q5107	Mvasi™	Bevacizumab-awwb	New Code
C9036	Onpattro™	Patisiran lipid complex injection, for intravenous use	Changed from C9399, J3490
C9037	Perseris™	Risperidone for extended-release injectable suspension	Changed from C9399, J3490
C9038	Poteligeo®	Mogamulizumab-kpkc injection, for intravenous use	Changed from C9399, J9999
J1301	Radicava®	Edaravone injection, for intravenous use	Changed from C9493
J7203	Rebiny®	Coagulation factor IX (recombinant), GlycoPEGylated lyophilized powder for solution for intravenous injection	Changed from C9468
J9312	Rituxan®	Rituximab, 100 mg	Changed from J9310
J9311	Rituxan Hycela®	Rituximab and hyaluronidase human injection, for subcutaneous use	Changed from C9467
J1628	Tremfya®	Guselkumab injection, for subcutaneous use	Changed from C9029
J3316	Triptodur®	Triptorelin pamoate for IM ER susp 22.5 mg	Changed from C9016
J1746	Trogarzo™	Ibalizumab-uiyk injection, for intravenous use	Changed from J3590
J2797	Varubi®	Injection, rolapitant, 0.5 mg	Changed from C9464
J9044	Velcade®	Bortezomib, 0.1 mg	Changed from J9041
J9153	Vyxeos™	Daunorubicin-cytarabine liposome for IV inj	Changed from J9024
C9039	Zemdri™	Plazomicin injection, for intravenous use	Changed from C9399, J3490
J3304	Zilretta®	Triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg	Changed from Q9493

*HCPCS codes were taken from the Centers for Medicare & Medicaid Services (CMS) HCPCS website at www.cms.gov/Medicare/Coding/HCPCSReleaseCodeSets/Alpha-Numeric-HCPCS.html.

PROVIDER Update



Health Net®
COMMUNITY SOLUTIONS

CONTRACTUAL | FEBRUARY 20, 2019 | UPDATE 19-132sum | 1 PAGE

Summary Update: Injectable Medication HCPCS/DOFR Crosswalk Reference Table Updated

Approved updates are effective April 24, 2019

On January 15, 2019, the Health Net* Pharmacy and Therapeutics (P&T) Committee approved updates to the Injectable Medication Healthcare Common Procedure Coding System (HCPCS)/Division of Financial Responsibility (DOFR) Crosswalk. The approved updates are effective April 24, 2019. The DOFR categories into which injectable medications are placed mirror the DOFR matrix categories located in the Health Net *Provider Participation Agreement (PPA)*. The update includes:

- The addition of 14 new medications and their DOFR categories.
- Updates and changes to 34 injectable medication procedure codes.

ADDITIONAL INFORMATION

To obtain a comprehensive description of the above topics, the complete update, 19-132, *Injectable Medication HCPCS/DOFR Crosswalk Reference Table Updated – 1st Quarter 2019*, is available on the Health Net provider portal at provider.healthnet.com in the Provider Library under *Updates and Letters > 2019*; search for provider update 19-132. Providers who do not have access to the Internet may request a print copy of update 19-132 by contacting the Health Net Provider Communications Department by email at provider.communications@healthnet.com.

Relevant sections of Health Net's provider operations manuals have been revised to reflect the information contained in this update as applicable. Provider operations manuals are available electronically in the Provider Library, located on Health Net's provider website at provider.healthnet.com.

Providers are encouraged to access Health Net's provider portal online at provider.healthnet.com for real-time information, including eligibility verification, claims status, prior authorization status, plan summaries, and more.

If you have questions regarding the information contained in this update, contact the Health Net Provider Services Center by email at provider_services@healthnet.com within 60 days, by telephone or through the Health Net provider website as listed in the right-hand column.

THIS UPDATE APPLIES TO
CAL MEDICONECT
PROVIDERS:

- Physicians
- Participating Physician Groups
- Hospitals
- Ancillary Providers

PROVIDER SERVICES

provider_services@healthnet.com
Los Angeles County – 1-855-464-3571
San Diego County – 1-855-464-3572
www.healthnet.com

PROVIDER COMMUNICATIONS

provider.communications@healthnet.com

* Health Net Community Solutions, Inc. is a subsidiary of Health Net, LLC and Centene Corporation. Health Net is a registered service mark of Health Net, LLC. All other identified trademarks/service marks remain the property of their respective companies. All rights reserved. Confidentiality Note for Fax Transmission: This facsimile may contain confidential information. The information is intended only for the use of the individual or entity named above. If you are not the intended recipient, or the person responsible for delivering it to the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained in this transmission is strictly PROHIBITED. If you have received this transmission in error, please notify the sender immediately by telephone or by return fax and destroy this transmission, along with any attachments.